Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ampersand Capital Partners
Manufacturing
CDMO Avid to go private in $1.1B deal
CDMO Avid has agreed to be acquired by funds managed by Ampersand and GHO Capital Partners in an all-cash deal worth $1.1 billion.
Fraiser Kansteiner
Nov 7, 2024 2:50pm
Nektar extends cash runway with $90M manufacturing plant sale
Nov 4, 2024 1:16pm
Tergus Pharma merges with fellow dermatology CDMO MedPharm
Jul 11, 2024 9:44am
CDMO Genezen expands to meet demand for viral vector production
Sep 17, 2021 8:50am
Germany's Vibalogics lays out $150M for Boston viral vector site
Nov 11, 2020 4:49pm
New CDMO, backed by private equity player, to make biologics
Oct 17, 2019 9:50am
